Knight Therapeutics (TSE:GUD) Given “Outperform” Rating at Raymond James

Raymond James restated their outperform rating on shares of Knight Therapeutics (TSE:GUD) in a report issued on Wednesday morning, BayStreet.CA reports. They currently have a C$10.25 price target on the stock. Raymond James also issued estimates for Knight Therapeutics’ Q4 2019 earnings at $0.05 EPS, FY2019 earnings at $0.20 EPS, Q2 2020 earnings at $0.04 EPS, Q3 2020 earnings at $0.04 EPS, Q4 2020 earnings at $0.05 EPS and FY2020 earnings at $0.17 EPS.

GUD has been the subject of several other research reports. Canaccord Genuity restated a buy rating and issued a C$8.50 price target on shares of Knight Therapeutics in a research note on Tuesday, October 15th. National Bank Financial upped their price objective on Knight Therapeutics from C$9.50 to C$10.00 and gave the company an outperform rating in a report on Tuesday, October 22nd. Finally, Bloom Burton upgraded Knight Therapeutics from an accumulate rating to a buy rating in a report on Tuesday, October 22nd.

Shares of GUD stock traded down C$0.08 during mid-day trading on Wednesday, hitting C$7.65. The company’s stock had a trading volume of 261,600 shares, compared to its average volume of 306,847. Knight Therapeutics has a 52-week low of C$7.10 and a 52-week high of C$8.88. The business has a 50-day moving average price of C$7.88 and a 200 day moving average price of C$7.64. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.03 and a current ratio of 10.29. The stock has a market cap of $1.14 billion and a price-to-earnings ratio of 50.66.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Read More: What is a dividend reinvestment plan?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.